Myomo Inc

MYO is in a Stage 4 decline with a clear support failure confirming medium-term bearish structure. Price is extended below declining short-term EMAs and oversold, making immediate selling unfavorable. We recommend waiting for a relief bounce into the 9/21 EMA zone or broken support-turned-resistance before re-engaging the sell side.

• ↑Q1 2026 revenue reached $10.1 M, a 3% year-over-year increase
• ↑Recurring patient revenue climbed from 25% to 49% of Q1 sales
• ↓Q1 2026 net loss narrowed to $3 M but operating expenses rose 64% YoY